Method of treating cancer with an anti tmeff2xcd3 bispecific antibody
Patent Information
- Application Number
- EP2023862610
- Authority / Receiving Office
- EP · EP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-10-28
- Filing Date
- 2023-09-06
- Publication Date
- 2025-07-16
AI Technical Summary
Current treatments for advanced prostate cancer, particularly metastatic castration-resistant prostate cancer, are ineffective in the long term as prostate cancer cells evolve to grow despite low androgen levels, leading to cancer regrowth and limited treatment options for patients resistant to current therapies.
Administration of an anti TMEFF2xCD3 bispecific antibody, which binds to TMEFF2 and CD3, to target and eliminate cancer cells, potentially inducing T cell activation and proliferation specifically in the prostate, thereby addressing the progression of prostate cancer.
The anti TMEFF2xCD3 bispecific antibody shows promise in reducing prostate-specific antigen levels and shrinking tumor lesions, indicating its effectiveness in treating metastatic castration-resistant prostate cancer by enhancing immune cell infiltration and activation within the prostate.
Smart Images
Figure 1.1